Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers

The personalization of cancer therapy for patients require characterization of uniqued and shared genetic data. Personalizing care in this way can have numerous benefits, such as identifying a subset of mutations that may be "actionable" with current drugs. However, the translation of clinical sequencing bears unique challenges including identifying patients who could benefit, developing informed consent and human subjects protections, outlining measurable outcomes, interpreting what results should be reported and validated, and how results should be reported. 

This MI-ONCOSEQ project has three themes:

  1. Project 1: “Clinical Genomic Study” will identify patients with advanced or refractory sarcoma or rare cancers who are eligible for clinical trials, consent them to the study, obtain biospecimens (tumor tissue, germline tissue), store clinical data, and assemble a multi-disciplinary Sequencing Tumor Board to deliberate on return of actionable or incidental genomic results
  2. Project 2: “Sequencing & Analysis” will process biospecimens and perform comprehensive sequencing and analysis of tumors to identify point mutations, copy number changes, rearrangements/gene fusions, and aberrant gene expression under CLIA/CAP guidelines
  3. Project 3: ”Ethics & Psychosocial Analysis” will evaluate the clinician and patient response to the informed consent process, delivery of genomic sequence results, and clinical use of genomic results